LOS ANGELES--(BUSINESS WIRE)--Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (Ritter Pharmaceuticals or the Company), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Michael Step, Chief Executive Officer, will present a corporate overview at the 2015 Aegis Growth Conference on Thursday, October 8, 2015.
Event: 2015 Aegis Growth Conference
Date: Thursday, October 8, 2015
Time: 10:00 a.m. PT
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharmaceuticals is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. The Company’s lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.